Altria sells nicotine products to adult consumers in the United States. Its biggest business is cigarettes, sold under the Marlboro brand through Philip Morris USA. It also sells machine-made large cigars under the Black & Mild brand, moist smokeless tobacco under Copenhagen and Skoal, oral nicotine pouches under the on! brand, and e-vapor products through NJOY. Customers pay for these products at stores, and Altria gets paid each time a product is sold. Because tobacco and nicotine products get used up quickly, customers come back and buy again and again. The diagram below traces where the money goes.
How Altria Makes Money
flowchart TD
A["Tobacco Leaf & Nicotine
Suppliers"] --> B["Manufacturing:
Cigarettes, Cigars,
Smokeless, E-Vapor"]
B --> C["Wholesale & Retail
Distribution"]
C --> D["Product Sales
$23.3B revenue"]
D --> E["Gross Profit
62.5% margin"]
E --> F["Operating Expenses
& R&D"]
F --> G["Operating Income
42.5% margin"]
G --> H["Free Cash Flow
$9.1B"]
H --> I["Brand Investment
& Talent Retention"]
I --> B
H --> J["Joint Venture:
Horizon HTS
75% stake"]
J --> D
H --> K["Equity Investments:
Cronos, ABI"]
K --> L["Future Growth
Opportunities"]
L --> B
Five years of financial data tell a clear story: revenue is falling, but the company is getting better at keeping the money it does earn. Revenue dropped from $25.1 billion in 2022 to $23.3 billion in 2025. That is a steady decline across every year in the period. But something interesting happened at the same time.
Annual Revenue 2022 to 2025 ($ billions)
Revenue has fallen each year as cigarette volumes decline.
Even as revenue fell, gross margin climbed every single year. In 2022, the company kept about 56.8 cents of gross profit for every dollar of revenue. By 2025, that number had risen to 62.5 cents. This means the company is raising prices faster than its volumes are falling. It is squeezing more profit out of fewer sales. Free cash flow, the money left over after running the business and maintaining its assets, held steady at around $8 to $9 billion per year across all four years.
Margins expanded even as volumes and revenue fell, showing the company's pricing power on its core products.
Cigarette shipment volume fell 10% in 2025 alone. The company estimates the entire cigarette industry shrank by about 6.5% in the fourth quarter of 2025. That decline is not just smokers quitting. A large part of it comes from people switching to illegal flavored e-vapor products that have flooded the market without government approval. The company estimates that these illegal products now make up roughly 70% of the entire e-vapor category. This is directly hurting NJOY, the e-vapor business Altria paid to acquire.
2025
crisis
NJOY Write-Down
In 2025, Altria recorded a total of $1.158 billion in goodwill write-downs on its NJOY e-vapor business, plus a further $970 million write-down of NJOY's intangible assets. The main cause was the continued spread of illegal flavored e-vapor products and an import ban on the NJOY ACE device due to a patent lawsuit. These charges pushed reported net earnings down to $6.947 billion in 2025 from $11.264 billion in 2024.
The NJOY situation illustrates the core tension in this business. Altria's cigarette profits are large and reliable today, but the cigarette market is structurally shrinking. The company has been trying to replace that volume with smoke-free products like NJOY e-vapor, the on! nicotine pouch, and a new heated tobacco joint venture called Horizon, built with Japan Tobacco. As of February 2026, Horizon had no products in the market yet, and it cannot sell anything until the FDA approves its products. Each of these new businesses faces its own set of obstacles.
What is an FDA Marketing Granted Order?
Before a company can legally sell a new tobacco or nicotine product in the United States, it must apply to the Food and Drug Administration (FDA) and receive approval. This approval is called a Marketing Granted Order. Without it, a product cannot legally be sold. The FDA can also revoke an approval it has already given, or ban a product it previously allowed.
NJOY's main product, the NJOY ACE, holds FDA approval but is currently banned from being imported into the United States because of a patent lawsuit brought by a competitor. That ban is being appealed, but it remains in effect during the appeal. A separate patent lawsuit from JUUL could create a similar ban on the NJOY Daily product. Meanwhile, the FDA has been slow to act against the illegal flavored products flooding the market, which are taking sales that would otherwise go to legal products like NJOY's.
$22.8B
Net debt at end of 2025, down from $23.7B in 2023, showing gradual deleveraging even while absorbing write-down charges.
The debt load is substantial but has been slowly declining. Net debt fell from $23.7 billion in 2023 to $22.8 billion in 2025. The company also pays a large and growing dividend, which it has committed to growing at a mid-single digit rate annually through 2028. That dividend commitment depends entirely on the cigarette business continuing to generate strong cash flow even as volumes fall. The company's own 2028 goals include maintaining an adjusted operating margin of at least 60% each year, and as of 2025, that goal was being met.
What is a Declining Market?
A declining market is one where the total number of products sold falls year after year, not because of one bad year but because of a long-term structural shift. For cigarettes, fewer people start smoking, more people quit, and some switch to other products. A company in a declining market can still make money by raising prices and cutting costs, but it cannot grow by selling more units.
The company also faces supply chain risks. It depends on a small number of suppliers for tobacco leaf, nicotine extract, and components like aluminum. Tariffs and geopolitical disruptions could raise the cost of these materials. On top of that, the company notes that declining social acceptance of tobacco makes it harder to recruit skilled workers, which is an unusual risk factor that most companies do not have to manage.
$9.1B
Free cash flow in 2025, matching the same level as 2023 despite falling revenue, showing the resilience of the cigarette cash engine.
The company's Optimize and Accelerate cost-cutting initiative, announced in October 2024, is expected to deliver at least $600 million in cumulative savings by the end of 2029, though it will cost approximately $175 million in charges to execute.
The Bet
Altria's cigarette business will keep generating enough cash, through price increases that offset shrinking volumes, to fund the transition into smoke-free products before the cigarette market declines too far. The smoke-free products, primarily NJOY e-vapor, on! nicotine pouches, and the Horizon heated tobacco joint venture, must reach meaningful scale and profitability while the cigarette engine is still running at full strength. If illegal e-vapor products continue to dominate the market, if the FDA delays approvals for Altria's new products, or if patent bans cripple NJOY, the replacement businesses may not be ready to carry the company before cigarette cash flow becomes too small to fund them.
Open question
Altria's cigarette business is one of the most profitable in the United States, and it keeps getting more efficient even as volumes fall. But the market it depends on is shrinking by design, and its most important bet on the future, NJOY, has already required billions in write-downs after import bans and illegal competition. Can price increases and cost cuts keep the cigarette business cash-generative long enough for the smoke-free products to actually replace it, or will the new businesses still be too small and too troubled when the old one can no longer carry the weight?
Compiled · 10-K · FY2025
Product Commercialization and Patent Litigation
The company faces import bans on NJOY ACE e-vapor products due to a patent lawsuit at the International Trade Commission. The company is appealing these bans, but they remain in effect during the appeal, preventing sales of this product in the United States. Additional patent lawsuits from competitors like JUUL could result in similar bans on other products like NJOY Daily.
Regulatory Authorization and FDA Review
The FDA controls whether new nicotine products can be sold, and the company cannot predict how fast the FDA will review applications or whether it will approve products. Long delays in FDA review allow competitors to gain market share, and the FDA could also order products already on the market to be removed if it decides they are not appropriate for public health.
Illicit Product Competition
Illegal flavored e-vapor products now make up the majority of the e-vapor market and are significantly reducing sales of the company's legal FDA-authorized e-vapor products. Recent government enforcement actions have not meaningfully reduced the availability of these illegal products, limiting the company's ability to grow its e-vapor business.
Raw Material and Supply Chain Disruption
The company depends on a small number of key suppliers and manufacturing facilities for tobacco leaf, nicotine extract, and component parts like aluminum and wood. Tariffs, geopolitical conflicts, weather, and reduced demand for tobacco could disrupt supply, increase costs significantly, or make certain materials unavailable.
NJOY Acquisition Impairment and Joint Venture Risk
The company recorded significant write-downs of the NJOY acquisition value in 2025 due to import bans on NJOY ACE and slower-than-expected enforcement against illicit products. The joint venture with Japan Tobacco for heated tobacco products (Horizon) depends on regulatory approvals, consumer preference changes, and other factors that could prevent it from generating expected revenue.
10-K Item 1A · Risk Factors
